Form 4/A for ZYME Zymeworks Inc.
Accepted 2022-12-23 00:00:00 ET · period of report 2022-12-12 · accession 0000899243-22-039332 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2022-12-23 | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $6.01 | -887 | 1,333 | -40% | -$5,331 |
| DA | 2022-12-23 | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | M - OptEx | $0.00 | +1,550 | 2,220 | +231% | $0 |
| DA | 2022-12-23 | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | M - OptEx | $0.00 | -1,550 | 1,550 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-12 | S | D | 887 | $6.01 | 1,333 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.99 to $6.035, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2022-12-12 | M | A | 1,550 | $0.00 | 2,220 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2022-12-12 | M | D | 1,550 | $0.00 | 1,550 | D | — · — to — | 1,550 Common Shares | (F4) Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. (F5) The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022. |